AllSci News
Spero secures USD 105m non-dilutive financing backed by Utebzi royalties
Cambridge, Massachusetts-based Spero Therapeutics (Nasdaq: SPRO) announced a USD 105 million non-recourse, non-dilutive royalty financing with affiliates of...
HuyaBio's tucidinostat-nivolumab combo cuts melanoma progression risk by 58% in Phase III trial
HuyaBio International, which operates out of San Diego and Shanghai, China, has reported statistically significant Phase III results for HBI-8000...
Spero expands into autoimmune disease via USD 1.1b Innovent anti-CD40L deal
Spero Therapeutics in-licenses Innovent's Fc-silent anti-CD40L antibody in up to USD 1.1 billion deal, marking a full pivot from antibiotics to autoimmune
AstraZeneca pays USD 600m upfront to reacquire worldwide rights to former China R&D asset from Dizal
AstraZeneca has entered a global exclusive license agreement with China-based Dizal Pharmaceutical (SSE: 688192) for Zegfrovy (sunvozertinib), an oral...
Hansoh extends cross-border licensing strategy with Avere Nasdaq deal, highlighting evolution of biotech “NewCo” model
Private US-based Avere Therapeutics, Inc. has entered into a definitive all-stock merger agreement with NextCure, Inc. (Nasdaq: NXTC), a US-based...
ADDF and Michael J. Fox Foundation pool USD 5m to develop shared Alzheimer’s-Parkinson’s biomarkers
The Alzheimer’s Drug Discovery Foundation (ADDF) and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced a USD 5 million research…
Alto Neuroscience raises USD 100m through stock offering as depression candidate enters Phase III
Mountain View, California-based Alto Neuroscience, Inc. (NYSE: ANRO) announced the pricing of an underwritten registered direct offering of common stock,...
US FDA approves Leqembi Iqlik for at-home subcutaneous initiation in early Alzheimer’s disease
The US FDA approved a supplemental Biologics License Application for Leqembi Iqlik (lecanemab-irmb) subcutaneous injection as an initiation dose for early Alzheimer’s…
BMS seeking first FDA approval for molecular glue mezigdomide in heavily pretreated multiple myeloma
The US FDA has accepted for review a New Drug Application submitted by Bristol Myers Squibb (NYSE: BMY) for mezigdomide in combination with carfilzomib and...
Novartis signs up to access Chai Discovery’s AI antibody platform
San Francisco-based Chai Discovery announced a collaboration with Novartis under which the Swiss pharmaceutical company will gain access to Chai’s generative AI…
Voyager reports durable six-month preclin safety data for Alzheimer's gene therapy ahead of Phase I
Voyager Therapeutics (Nasdaq: VYGR) reported six-month preclinical toxicology data for VY1706 Alzheimer's gene therapy candidate at the Alzheimer's...
GSK's PD-1 dostarlimab moves closer to surgery-free treatment for locally advanced rectal cancer
GSK (NYSE: GSK) reported positive interim results on July 14 from the registrational AZUR-1 trial of dostarlimab (Jemperli) in patients with stage II/III...
Alkermes' alixorexton sustains narcolepsy wakefulness gains through nine months of extension study
Nine months of sustained wakefulness data from an ongoing long-term extension study of alixorexton narcolepsy treatment may be the most consequential...
CSPC's bispecific HER2 antibody and albumin-bound docetaxel secure BTD in China
China's NMPA granted Breakthrough Therapy Designation to CSPC's albumin-bound docetaxel (HB1801) combined with the HER2 bispecific antibody anbenitamab (KN026) for first-line unresectable or metastatic HER2-positive breast cancer.
Servier acquires Edgewise's muscular dystrophy business for USD 2.65 billion, gaining sevasemten rights
France-based Servier has completed its acquisition of the muscular dystrophy business of Boulder, Colorado-based Edgewise Therapeutics (Nasdaq: EWTX) for up...
The AllSci Brief
Free, systematic R&D and deal news. Daily.